Research Topics
| L B TravisSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Mortality after cerebral angiography with or without radioactive Thorotrast: an international cohort of 3,143 two-year survivorsL B Travis
Radiation Epidemiology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
Radiat Res 156:136-50. 2001..The cumulative excess risk of cancer death remained high up to 50 years after injection with >20 ml Thorotrast and approached 50%...
Lung cancer following chemotherapy and radiotherapy for Hodgkin's diseaseLois B Travis
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
J Natl Cancer Inst 94:182-92. 2002..We quantified the risk of treatment-associated lung cancer, taking into account tobacco use...
Clinical features of hematopoietic malignancies and related disorders among benzene-exposed workers in China. Benzene Study GroupM S Linet
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892 7368, USA
Environ Health Perspect 104:1353-64. 1996....
Lung cancer after treatment for Hodgkin's disease: focus on radiation effectsE S Gilbert
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda Maryland 20852 7238, USA
Radiat Res 159:161-73. 2003....
Risk of treatment-related esophageal cancer among breast cancer survivorsL M Morton
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD 20892, USA
Ann Oncol 23:3081-91. 2012..Radiotherapy for breast cancer may expose the esophagus to ionizing radiation, but no study has evaluated esophageal cancer risk after breast cancer associated with radiation dose or systemic therapy use...
Lung cancer after Hodgkin lymphoma: the roles of chemotherapy, radiotherapy and tobacco useL B Travis
Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI, National Institutes of Health, Bethesda, Maryland, USA
Radiat Res 163:695-6. 2005
Cancer risk following exposure to Thorotrast: overview in relation to a case reportL B Travis
Radiation Epidemiology Branch, National Cancer Institute, National Institutes of Health, U S Department of Health and Human Services, Rockville, MD 20852
Health Phys 63:89-97. 1992..The skeleton of USUR Case 1001, however, contained significant levels of radioactivity. Other tissues evaluated in USUR Case 1001 included lung, eye, kidney, and breast, which did not contain elevated levels of radioactivity...
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional studyR E Curtis
Division of Cancer Epidemiology, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
Blood 94:2208-16. 1999..0% +/- 2.9% and 22% +/- 17.9%, respectively. We conclude that factors associated with altered immunity and T-cell regulatory mechanisms are predictors of both early- and late-onset PTLD...
Mortality among benzene-exposed workers in ChinaR B Hayes
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 7368, USA
Environ Health Perspect 104:1349-52. 1996..01) and lung cancer (ptrend = 0.01) increased with increasing cumulative exposure to benzene. Investigations continue to relate benzene exposure to specific lymphatic and hematopoietic malignancies and other causes of death...
Solid tumors after chronic lymphocytic leukemiaM Hisada
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA
Blood 98:1979-81. 2001..91) and for cancers of the stomach (O/E = 1.76) and bladder (O/E = 1.52) among women. Additional investigations of cancers after CLL are needed to explore the role of immunologic impairment and/or other etiologic influences...
Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphomaL J Worrillow
Department of Biology, University of York, Heslington, York, UK
J Med Genet 45:142-6. 2008..We hypothesised that a common substitution in the basal promoter of MLH1 (position -93, rs1800734) modifies the risk of cancer after methylating chemotherapy...
